Pharmagreen Biotech Inc.
PHBI
$0.0011
$0.000.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -28.57% | 13.33% | 168.75% | 330.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -28.57% | 13.33% | 168.75% | 330.00% | -- |
| Cost of Revenue | -34.62% | -19.05% | 42.86% | 90.00% | -- |
| Gross Profit | -23.53% | 88.89% | 1,050.00% | -- | -- |
| SG&A Expenses | -35.78% | -47.38% | -47.95% | -55.95% | -65.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.72% | -47.22% | -47.70% | -55.74% | -64.83% |
| Operating Income | 35.83% | 47.64% | 48.34% | 56.30% | 65.23% |
| Income Before Tax | 66.42% | -76.62% | 19.31% | -510.36% | 27.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 66.42% | -76.62% | 19.31% | -510.36% | 27.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 66.44% | -76.60% | 19.33% | -510.36% | 27.77% |
| EBIT | 35.83% | 47.64% | 48.34% | 56.30% | 65.23% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 71.43% | -23.08% | 33.33% | -450.00% | 41.67% |
| Normalized Basic EPS | 87.50% | 0.00% | 62.50% | -150.00% | 46.67% |
| EPS Diluted | 71.43% | -23.08% | 33.33% | -175.00% | 46.15% |
| Normalized Diluted EPS | 87.50% | 0.00% | 62.50% | -66.67% | 50.00% |
| Average Basic Shares Outstanding | 29.25% | 42.29% | 39.70% | 30.22% | 22.45% |
| Average Diluted Shares Outstanding | 29.25% | 42.29% | 39.70% | 16.36% | 9.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
